Effects of gray drugs in patients with coronary heart disease: A network Meta-analysis

doi:10.12092/j.issn.1009-2501.2018.03.010

Abstract

Abstract:

AIM: To evaluate the clinical effect of gray drugs such as clopidogrel, prasugrel and ticagrelor combined aspirin using network Meta-analysis by comparing major adverse cardiac events. METHODS: Database Pubmed, Cochrane Central Register of Controlled Trials, CBM, CNKI, VIP, Wanfang Data in both English and Chinese were retrieved. RCTs using gray drugs such as clopidogrel, prasugrel, ticagrelor, cangrelor, sarpogrelate in coronary patients were then collected. Indirect step-by-step comparison was adopted for Meta-Analysis on Stata. RESULTS: A total of 33 trials entered into the study. There was significant difference between ticagrel and clopidogrel (OR=0.70, 95% CI: 0.64-0.77, P<0.001). There was no significant difference between prasugrel and clopidogrel (OR=0.92, 95% CI: 0.84-1.01, P=0.487). There was significant difference between ticagrel and prasugrel (OR=0.76, 95% CI: 0.67-0.86, P<0.001). CONCLUSION: Ticagrelor combined aspirin therapy showed best curative effect in preventing major adverse cardiovascular events of coronary heart disease, prasugrel the second, and clopidogrel the last.

Key words: clopidogrel, prasugrel, ticagrelor, coronary heart disease, network Meta-analysis

CLC Number:

R541.4

WANG Weiyu, YU Hao. Effects of gray drugs in patients with coronary heart disease: A network Meta-analysis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 301-307.

References

［1］杨槐旺.冠心病治疗中氯吡格雷的临床应用效果分析［J］.北方药学,2015,12(4): 69.
［2］邝洁云, 谭洁, 邹建军,等.氯吡格雷与质子泵抑制剂联用治疗冠心病安全性的系统评价［J］.中国循证医学杂志,2011,11(3):283-291.
［3］Gurbel PA, Bliden KP, Hiatt BL,et al.Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity［J］.Circulation, 2003,107(23):2908-2913.
［4］钟桃娟, 柯于梵, 萧湛潮,等.冠脉支架术后口服多种P2Y12受体拮抗剂发生抵抗的影响因素分析［J］.中山大学学报(医学科学版), 2015, 36(5):704-709.
［5］张天嵩, 钟文昭, 李博.实用循证医学方法学.第2版［M］.长沙:中南大学出版社, 2014.
［6］Adams HP Jr.Ticagrelor, a new antiplatelet agent, for prevention of ischemic events in patients with coronary artery disease［J］. Curr Neurol Neurosci Rep, 2010,10(1):4-6.
［7］Dridi NP, Johansson PI, Clemmensen P, et al. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response--the TAILOR (Thrombocytes and individuaLization of oral antiplatelet therapy in percutaneous coronary intervention) randomized trial ［J］. Platelets, 2014, 25(7):506-512.
［8］Isshiki T, Kimura T, Ogawa H, et al. Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention［J］.Circ J,2014, 78(12):2926-2934.
［9］Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization［J］.N Engl J Med,2012, 367(14):1297-1309.
［10］Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study ［J］.J Am Coll Cardiol,2012, 59(24):2159-2164.
［11］Wiviott SD, White HD, Ohman EM, et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial ［J］.Lancet,2013, 382(9892):605-613.
［12］Xia JG, Qu Y, Hu SD, et al.［Midterm follow-up outcomes of ticagrelor on acute ST segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention］［J］.Beijing Da Xue Xue Bao Yi Xue Ban,2015, 47(3):494-498.
［13］陈春燕.替格瑞洛用于急性心肌梗死的临床疗效及安全性研究［J］.中国药业,2014, 23(4):61-63.
［14］陈建玲, 谈晓侠, 刘会玲.替格瑞洛对经皮冠状动脉介入术后预后效果的影响［J］.中国药业, 2016, 25(2):32-34.
［15］陈学智, 唐强, 曲华清,等.替格瑞洛抗血小板治疗不稳定性心绞痛经皮冠状动脉介入术后患者的临床观察［J］.中国医院用药评价与分析, 2015,15(6):745-746.
［16］杜小娇. 替格瑞洛与氯吡格雷对急性冠脉综合征患者抗血小板疗效比较［D］. 苏州大学, 2015.
［17］侯方杰, 王晏平, 吴娜,等.替格瑞洛在急诊PCI术中应用的疗效及安全性观察［J］.中国循证心血管医学杂志, 2015, 7(4):533-536.
［18］姜述斌, 葛振嵘, 李岚,等.早期应用替格瑞洛对急性冠状动脉综合征急诊介入术后患者预后的影响［J］.临床心血管病杂志,2015, 31(7):712-716.
［19］李康博, 刘晓坤, 张琦,等.低剂量替格瑞洛治疗稳定型冠心病患者的疗效及安全性评价［J］.复旦学报·医学版,2016, 43(2):164-169.
［20］李丽, 曹学彬, 石妍,等.替格瑞洛和氯吡咯雷抗血小板治疗急性冠脉综合征的近期疗效和安全性比较［J］.医学临床研究,2016,33:1385-1387.
［21］李阳, 王晓强, 刘亚宁.替格瑞洛治疗急性ST段抬高型心肌梗死的临床效果及安全性分析［J］.社区医学杂志,2016,14(3):68-69.
［22］马林, 胡素玲, 李爱玲,等.替格瑞洛在氯吡格雷抵抗急性心肌梗死患者PCI术后抗血小板治疗中的应用价值［J］.河北医学,2016, 22(3):402-405.
［23］毛霄鹏, 严语.替格瑞洛与氯吡格雷对经皮冠状动脉介入术治疗的ST段抬高型心肌梗死患者的临床疗效［J］.中国临床药理学杂志, 2016, 32:786-788.
［24］孟令诗.替格瑞洛治疗急性冠脉综合征的临床疗效观察［J］.中国实用医药,2014,8(21):149-150.
［25］牛红霞, 褚晓雯, 康枫,等.替格瑞洛在急性ST段抬高型心肌梗死急诊介入术中的应用效果观察［J］.疑难病杂志,2016, 15(10):994-997.
［26］祁庆姣, 于长青.替格瑞洛在急性冠脉综合征患者介入治疗中的近期疗效评价［J］.成都医学院学报,2015,10(6):708-711.
［27］王星, 浦奎, 贾忠伟.替格瑞洛用于氯吡格雷抵抗的经皮冠状动脉介入患者40例［J］.中国药业, 2015, 24(15):74-75.
［28］王子良, 周立华, 刘伟霞,等.替格瑞洛治疗急性心肌梗死的临床应用［J］.中国实用医药, 2016,11(16):198-199.
［29］魏雪梅, 朱庆华, 谷世奎,等.替格瑞洛在氯吡格雷抵抗急性心肌梗死患者PCI术后抗血小板治疗中的应用效果［J］.山东医药,2015, 15(55):46-48.
［30］夏志琦, 王小庆, 孙晓红,等.急性冠状动脉综合征患者替格瑞洛治疗效果观察［J］.中国现代药物应用,2016,10(5):192-193.
［31］徐广.经皮冠脉介入联合替格瑞洛治疗急性心肌梗死34例临床观察［J］.安徽医药,2015,19(11):2203-2205.
［32］张冬青, 田凤军.替格瑞洛治疗急性冠脉综合征的临床疗效观察［J］.中国实用医药,2013,8(31):154-155.
［33］张鞠蕾, 王宾, 陈华,等.替格瑞洛在急诊经皮冠状动脉介入治疗抗栓中有效性及安全性研究［J］.临床急诊杂志,2015,16(10):756-759.
［34］张明亮, 于海波, 张立敏,等.替格瑞洛对NSTEMI急诊PCI患者血小板聚集率、CRP及预后的影响［J］.中华临床医师杂志·电子版, 2016, 10(11):216-217.
［35］张颖, 汪蔚青, 杨伟.替格瑞洛和氯吡格雷治疗伴缺血性脑梗死史急性冠脉综合征的疗效比较［J］.现代药物与临床,2016, 31(4):449-453.
［36］赵子粼, 黄梁艳, 覃善都.不同抗血小板药物对急性冠脉综合征患者血小板活化指标的影响［J］.实用老年医学,2015, 29(10):847-849.
［37］周学敏, 郭莉青, 王燕庆,等.氯吡格雷与替格瑞洛治疗急性冠状动脉综合征合并慢性阻塞性肺病的疗效及安全性比较［J］.中国介入心脏病学杂志,2016,24(4):211-215.
［38］朱华强.替格瑞洛和氯吡格雷对急性冠脉综合征患者的临床疗效对比分析［J］.中国现代药物应用, 2016, 10(5):5-6.
［39］黄健中.口服抗血小板药物在冠心病52例治疗中的临床分析［J］.数理医药学杂志,2015, 28(6):1177-1178.
［40］崔文章, 刘和平.STEMI急诊PCI治疗联用替格瑞洛与11b/111a受体拮抗剂不明显增加出血风险的分析［J］.中外医疗, 2016, 35(13):105-106.
［41］董金虎, 付晓勤.替格瑞洛对急性冠状动脉综合征多支病变行PCI介入治疗患者的有效性及安全性分析［J］.中国实用医药,2016, 11(13):162-163.
［42］黄丽雅.替格瑞洛应用于急性心肌梗死患者PCI术后抗血小板的治疗效果研究［J］.现代诊断与治疗,2016, 27(14):2595-2596.
［43］徐洋.替格瑞洛与氯吡格雷治疗急性冠脉综合征临床疗效对比［J］.中国卫生标准管理, 2016, 7(9):113-114.
［44］刘小熊, 夏豪, 张琰,等.替格瑞洛与氯吡格雷治疗急性冠脉综合征疗效比较的Meta分析［J］.中国循证心血管医学杂志, 2014, 6(4): 396～399.
［45］翟鹏.替格瑞洛与氯吡格雷治疗急性冠脉综合征疗效与安全性meta分析［D］.山西医科大学, 2015.
［46］张文佳.普拉格雷和氯吡格雷对冠心病患者血小板的应性作用的Meta分析［D］. 山东大学, 2015.
［47］王欣, 夏豪, 童随阳,等.普拉格雷和氯吡格雷对冠心病患者疗效和安全性的Meta分析［J］.医学研究杂志,2015, 44(2):49-54.

[1]	PANG Shengfeng, ZHANG Jing, WU Ningning, LI Ru, CAO Jun, HE Shenghu. Efficacy of antiplatelet therapy with ticagrelor monotherapy after short-term double antibody therapy in patients with acute coronary syndrome after PCI [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1004-1009.
[2]	WANG Qi, ZOU Yunzeng. New development of lipid-lowering therapy of coronary heart disease: Evinacumab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 362-364.
[3]	WANG Qi, ZOU Yunzeng. New development of lipid-lowering therapy of coronary heart disease: Inclisiran [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 365-368.
[4]	WANG Qi, ZOU Yunzeng. New development of lipid-lowering therapy of coronary heart disease: Bempedoic acid [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 369-372.
[5]	CHANG Shufu . Progress of medical treatment of coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 405-408.
[6]	WANG Ruijie, WANG Liang, XU Dan, ZHOU Miaomiao, LI Jiming. Effects of PCSK9 inhibitors on blood lipids and inflammatory factors in patients with coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 409-417.
[7]	YAN Lei, JIANG Haibin, NAFEISHA Paerhati, REZIWANGULI Yikemu, GENG Boyu, MAIERHABA Maimaitiaili. Effects of different doses of dexmedetomidine on non-cardiac surgery stress and postoperative sleep in patients with coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1340-1346.
[8]	LU Xiya, LI Yuxing, LI Wenzhi, PENG Yuanyuan, HU Yi, WAN Li, CHEN Bilian. Analysis of prescribing of antiplatelet drug in patients with coronary heart disease in department of geriatrics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1285-1291.
[9]	XIA Chunyong, ZHANG Zuowen, HE Xiaoyan, LIU Jie, LI Xiaoya, CHANG Qiuhong, QIN Lijuan, CAO Zhenming, DING Ling. Correlation between CYP2C19 gene polymorphism and individualized medication in patients with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 318-323.
[10]	YUAN Zhen, CHEN Bilian. Review of bleeding events in clinical studies of clopidogrel [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 341-349.
[11]	XU Honglei, XU Bingxin, ZU Qing, ZHAO Yan, GAO Pengfei, YU Yang. Effects of CYP2C19 gene polymorphism on the clinical prognosis of clopidogrel in elderly patients with acute cerebral infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1014-1020.
[12]	PENG Jing, LIU Jun, XU Huifang, LI Yueran, JIANG Jia, WANG Sheng, ZHOU Dexi, ZHU Yanhong, YANG Kui, LUAN Jiajie. Correlation study between cytochrome P4502C19 gene polymorphism or metabolic type and ADP induced-platelet aggregation inhibition and clopidogrel resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 746-751.
[13]	YANG Rui, LIU Hui, CHEN Zeheng, QI Tingting，ZHANG Zanling, QU Qiang. Clinical pharmacists use CYP2C19 genotyping test to guide individual medication therapy of Clopidogrel and to evaluate the efficacy of treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 938-943.
[14]	CHEN Miao, ZHANG Xinjin, MENG Hongli, YANG Bei, SONG Lijuan, ZOU Chuannan, GUAN Yingxia. Therapeutic effect of bisoprolol combined with salvianolate on patients with coronary heart disease after PCI [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 451-457.
[15]	PENG Qiuju, YAN Huacheng, SHI Lei. Advances in the relationship between cytochrome P450 SNP and susceptibility to coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 477-480.